Luminous Mind, Inc. targets a billion-dollar market opportunity after securing a U.S. patent for non-hallucinogenic psychedelic compounds, sparking interest in potential strategic partnerships.
Luminous Mind, Inc. has secured a U.S. patent for non-hallucinogenic psychedelic mushrooms, positioning the company to capture a significant share of the wellness and pharmaceutical markets. By actively seeking strategic partnerships across the nutraceutical and pharmaceutical sectors, the company is scaling its commercialization strategy to address a projected billion-dollar-plus market opportunity.
The patent covers non-hallucinogenic psychedelic mushrooms, allowing for therapeutic applications without the psychoactive effects typically associated with such compounds.
The company is focused on forming strategic partnerships with nutraceutical, supplement, and pharmaceutical firms to commercialize its breakthrough products.
Luminous Mind, Inc. (LMI) has secured a U.S. patent for non-hallucinogenic psychedelic mushrooms, positioning the firm to tap into a potential billion-dollar market. The company is now actively seeking strategic partnerships across the pharmaceutical and nutraceutical sectors to commercialize its breakthrough technology.
The patent covers non-hallucinogenic psychedelic mushrooms, which allows the company to pursue therapeutic applications without the psychoactive effects typically associated with these compounds.